Sarepta Therapeutics (SRPT)

Jan 16, 2025, 1:23 PM EST - 1 day ago

Sarepta Therapeutics: Guidance Suggests A Year Of Upside Likely

Jan 13, 2025, 12:25 PM EST - 4 days ago

Sarepta Therapeutics Reports Preliminary* Fourth Quarter and Full-Year 2024 Net Product Revenue

Jan 7, 2025, 11:19 AM EST - 10 days ago

Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference

Jan 6, 2025, 8:30 AM EST - 11 days ago

Sarepta Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 31, 2024, 4:10 PM EST - 17 days ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 20, 2024, 4:45 PM EST - 4 weeks ago

Sarepta wins $115.2 million US drug patent verdict from Japan's Nippon Shinyaku

Dec 18, 2024, 8:30 AM EST - 4 weeks ago

Sarepta Therapeutics Completes Enrollment in EMERGENE, a Phase 3 Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4

Nov 26, 2024, 7:00 AM EST - 7 weeks ago

Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs

ARWR

Nov 8, 2024, 3:02 PM EST - 2 months ago

Sarepta Therapeutics: BLA Filing Of SRP-9003 For LGMD Is The Next Step

Nov 7, 2024, 2:10 AM EST - 2 months ago

Sarepta Therapeutics, Inc. (SRPT) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:05 PM EST - 2 months ago

Sarepta Therapeutics Announces Third Quarter 2024 Financial Results and Recent Corporate Developments

Oct 23, 2024, 8:30 AM EDT - 3 months ago

Sarepta Therapeutics to Announce Third Quarter 2024 Financial Results

Oct 21, 2024, 9:01 AM EDT - 3 months ago

This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

GEV BKV ESE GRDN

Sep 26, 2024, 8:30 AM EDT - 4 months ago

Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 2024 World Muscle Society Congress

Sep 18, 2024, 11:59 PM EDT - 4 months ago

Sarepta Therapeutics Muscles Up In DMD Race

Sep 16, 2024, 8:30 AM EDT - 4 months ago

Sarepta Therapeutics Appoints Deirdre Connelly to its Board of Directors

Sep 5, 2024, 9:00 AM EDT - 4 months ago

Sarepta Therapeutics Announces Recipients of the 7th Annual Route 79, The Duchenne Scholarship Program, for the 2024-2025 Academic Year

Aug 30, 2024, 8:30 AM EDT - 5 months ago

Sarepta Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 14, 2024, 2:39 PM EDT - 5 months ago

Biotech Stock Flashing Bull Signal

Aug 7, 2024, 6:25 PM EDT - 5 months ago

Sarepta Therapeutics, Inc. (SRPT) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:05 PM EDT - 5 months ago

Sarepta Therapeutics Announces Second Quarter 2024 Financial Results and Recent Corporate Developments

Jul 29, 2024, 7:00 AM EDT - 6 months ago

Sarepta Therapeutics to Announce Second Quarter 2024 Financial Results

Jul 24, 2024, 6:08 PM EDT - 6 months ago

Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity

Jun 25, 2024, 9:00 AM EDT - 7 months ago

Will Elevidys Approval Make Sarepta Stock An Acquisition Target?

Jun 22, 2024, 6:47 AM EDT - 7 months ago

Sarepta Therapeutics: Pushing The Edge And Creating The Horizon

Jun 21, 2024, 7:05 PM EDT - 7 months ago

Sarepta CEO on what's next after expanded muscular dystrophy drug approval

Jun 21, 2024, 5:45 PM EDT - 7 months ago

TD Cowen's Ritu Bara talks Sarepta stock skyrocketing on FDA gene therapy approval

Jun 21, 2024, 1:52 PM EDT - 7 months ago

Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty

CTLT NVO

Jun 21, 2024, 1:21 PM EDT - 7 months ago

Wall Street Beats to Host Conference Call with Sarepta CEO on Ground-Breaking Expanded Label Approval

Jun 21, 2024, 12:50 PM EDT - 7 months ago

Sarepta's Expanded FDA Approval For Elevidys Potentially Shaping Future FDA Reviews, Analyst Says

Jun 21, 2024, 12:14 PM EDT - 7 months ago

Sarepta (SRPT) Soars on FDA Approval on Muscular Dystrophy Treatment

Jun 21, 2024, 10:10 AM EDT - 7 months ago

Sarepta Soars on Expanded Approval for Muscular Dystrophy Drug

Jun 21, 2024, 9:31 AM EDT - 7 months ago

Sarepta Therapeutics Soars on Expanded Approval for Its Muscular Dystrophy Drug

Jun 21, 2024, 8:05 AM EDT - 7 months ago

Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug

Jun 21, 2024, 7:43 AM EDT - 7 months ago

Sarepta Stock Surges on Expanded Approval for Elevidys. What Wall Street Thinks.

Jun 21, 2024, 7:39 AM EDT - 7 months ago

FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy

Jun 21, 2024, 6:53 AM EDT - 7 months ago

Sarepta surges as investors cheer expanded use of gene therapy

Jun 21, 2024, 5:12 AM EDT - 7 months ago

Why has the Sarepta stock price (SRPT) gone up more than 35%?

Jun 20, 2024, 7:41 PM EDT - 7 months ago

Sarepta Therapeutics receives expanded approval for Elevidys

Jun 20, 2024, 5:43 PM EDT - 7 months ago

US FDA approves expanded use of Sarepta's Duchenne gene therapy

Jun 20, 2024, 5:02 PM EDT - 7 months ago

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above

Jun 17, 2024, 1:29 PM EDT - 7 months ago

Sarepta Therapeutics: Navigating Elevidys Upside Potential

Jun 13, 2024, 8:49 AM EDT - 7 months ago

Pfizer's gene-therapy trial failure boosts Sarepta's stock

PFE

May 30, 2024, 8:07 AM EDT - 8 months ago

Sarepta Therapeutics stock to enter S&P MidCap 400: Should you buy?

May 3, 2024, 10:07 AM EDT - 9 months ago

Gene Therapy Pioneer Jerry R. Mendell, M.D.

May 1, 2024, 5:22 PM EDT - 9 months ago

Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript

May 1, 2024, 4:05 PM EDT - 9 months ago

Sarepta Therapeutics Announces First Quarter 2024 Financial Results and Recent Corporate Developments

Apr 24, 2024, 8:30 AM EDT - 9 months ago

Sarepta Therapeutics to Announce First Quarter 2024 Financial Results

Apr 11, 2024, 2:27 AM EDT - 10 months ago

Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy

Apr 6, 2024, 7:10 AM EDT - 10 months ago

Outperforming ETF manager names a potential ‘50-bagger' in the stock market

CI ISRG LLY PCT PINK